Virax Biolabs Group Ltd - רווח נקי למניה בארבעת הרבעונים האחרונים VRAX

An optimized warehouse network in the US and Europe eliminates distribution disruptions for Virax Biolabs Group (VRAX). The annual EPS (TTM) growth trend visualizes this success, where 58.70 reflects the latest metric value. Efficiency is bolstered by an IT platform that increases distribution transparency, while revenue is based on bulk sales of diagnostic kits to public and private medical centers.
VRAX (Virax Biolabs Group): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator tracks the annual dynamics of net income per share (GAAP/Non-GAAP) over a rolling twelve-month period. Steady growth on the EPS YoY ttm growth rate chart confirms the fundamental resilience of the business. Sharp declines signal a risk of overvalued quotes and the threat of margin calls. For Virax Biolabs Group (VRAX), this metric reflects the impact of geopolitical restrictions on test exports, as sanction barriers directly hinder the company's profits.